Venlafaxine in the treatment of panic disorder
Authors Martin A Katzman, Leslie Jacobs
Published 15 March 2007 Volume 2007:3(1) Pages 59—67
Martin A Katzman1,2,3, Leslie Jacobs1
1START Clinic for the Mood and Anxiety Disorders, Toronto, ON, Canada; 2University of Toronto, ON, Canada; 3Northern Ontario School of Medicine, Toronto, ON, Canada
Abstract: Venlafaxine XR is a novel, dual acting SNRI antidepressant, which inhibits both serotonin and norepinephrine reuptake. Controlled trials have demonstrated the efficacy and safety of venlafaxine in the treatment of panic disorder. Generally well tolerated, with side effects that usually abate with continued treatment, venlafaxine is an important option to the SSRIs for the treatment of patients with panic disorder.
Keywords: anxiety disorders, panic disorder, antidepressant therapy, remission, venlafaxine, selective serotonin norepinephrine reuptake inhibitor